BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, February 14, 2025
Breaking News: BioWorld by Clarivate releases comprehensive 2024 year in review
See today's BioWorld Science
Home
» Series A financing at Rheumagen supports HLA gene-editing therapies for autoimmune diseases
To read the full story,
subscribe
or
sign in
.
Musculoskeletal
Series A financing at Rheumagen supports HLA gene-editing therapies for autoimmune diseases
Jan. 10, 2025
No Comments
The financing will enable progression of RG-0401.
BioWorld Science
Financings
Musculoskeletal
Gene therapy
Series A